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ABSTRACT
Background Intravenous insulin infusions are considered 
the treatment of choice for critically ill patients and non-
critically ill patients with persistent raised blood glucose 
who are unable to eat, to achieve optimal blood glucose 
levels. The benefits of using intravenous insulin infusions 
as well as the problems experienced are well described 
in the scientific literature. Traditional approaches for 
improving patient safety have focused on identifying 
errors, understanding their causes and designing solutions 
to prevent them. Such approaches do not take into account 
the complex nature of healthcare systems, which cannot 
be controlled solely by following standards. An emerging 
approach called Resilient Healthcare proposes that, to 
improve safety, it is necessary to focus on how work can 
be performed successfully as well as how work has failed.
Methods and analysis The study will be conducted at 
Oxford University Hospitals NHS Foundation Trust and 
will involve three phases. Phase I: explore how work 
is imagined by analysing intravenous insulin infusion 
guidelines and conducting focus group discussions 
with guidelines developers, managers and healthcare 
practitioners. Phase II: explore the interplay between how 
work is imagined and how work is performed using mixed 
methods. Quantitative data will include blood glucose 
levels, insulin infusion rates, number of hypoglycaemic and 
hyperglycaemic events from patients’ electronic records. 
Qualitative data will include video reflexive ethnography: 
video recording healthcare practitioners using intravenous 
insulin infusions and then conducting reflexive meetings 
with them to discuss selected video footage. Phase III: 
compare findings from phase I and phase II to develop a 
model for using intravenous insulin infusions.
Ethics and dissemination Ethical approvals have been 
granted by the South Central—Oxford C Research Ethics 
Committee, Oxford University Hospitals NHS Foundation 
Trust and University of Reading. The results will be 
disseminated through presentations at appropriate 
conferences and meetings, and publications in peer-
reviewed journals.
InTRoduCTIon
Healthcare organisations are now highly 
complex and staff are becoming more stressed 
due to rising pressures and the high risk 
nature of their work.1 Globally, it is reported 
that about 10% of hospitalised patients expe-
rience adverse events.1 2 Medications can 
present a considerable risk to patients due to 
their potency and the systems in which medi-
cines are used are one of the main causes of 
harm and errors in healthcare. Prescribing 
medication is the most common interven-
tion in healthcare and medication errors are 
considered to be the most preventable.3 
Insulin is a high-risk medication that can 
cause significant patient harm or death when 
used incorrectly.4 Although intravenous 
insulin is extremely effective at reducing 
blood glucose levels quickly for hospitalised 
patients, this characteristic also carries the 
risk of causing patient harm due to errors 
in how it is used. Insulin requires additional 
measures to ensure safe prescribing, moni-
toring and administration.4 5 Based on the 
National Diabetes Inpatient Audit (NaDIA) 
Strengths and limitations of this study
 ► This study will test the feasibility of using a novel 
combination of methods to understand the clinical 
work of managing intravenous insulin infusions to 
understand Resilient Healthcare.
 ► In collaboration with healthcare practitioners, this 
study will result in the development of practice rec-
ommendations to improve the management of pa-
tients requiring intravenous insulin infusions.
 ► This study will produce a model of the use of intra-
venous insulin infusions.
 ► Although there are criticisms with the use of a video 
approach in that it might affect the behaviour of par-
ticipants, a recent review challenged this assump-
tion and found no evidence that video recording 
causes significant alteration to the usual way par-
ticipants behave.
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(2018),6 four out of 10 insulin-treated inpatients expe-
rienced a medication error during their hospital stay. 
Inappropriate intravenous insulin infusion rates, inap-
propriate duration, inappropriate transfer to subcuta-
neous insulin and infrequent monitoring are examples of 
problems with the use of intravenous insulin infusions.6
Traditional approaches to increase safety have focused 
on identifying systemic weaknesses that contribute to 
errors, for example, through incident reporting,7 audit8 
and complaints.9 These initiatives then result in solutions 
to prevent future recurrence. Common solutions have 
included double checking,10 standardisation of intra-
venous insulin infusion guidelines and education and 
training of healthcare staff.11 Such approaches do not 
always take into account the complex nature of health-
care systems, which cannot be controlled solely by stan-
dards or procedures. Yet, major investments to enhance 
patient safety have focused on these and have not resulted 
in convincing reductions in risk, error, harm or death due 
to incidents.12
This disappointing track record of safety improvement 
informed by traditional approaches has led to a call for a 
change in thinking about safety. An emerging approach 
called Resilient Healthcare proposes that although it is 
necessary to understand what goes wrong, there is also 
value and lessons to be learnt from what goes right.13
BACkgRound
Resilient Healthcare is defined as ‘the ability of the 
healthcare organisation to adjust its functioning prior to, 
during, or following events and thereby sustain required 
operations under both expected and unexpected condi-
tions’.13 It proposes that the complexity and variability in 
the healthcare environment is key to understanding how 
errors occur.13 This approach considers healthcare prac-
tice not as a problem to be solved or requiring standard-
isation. Instead, existing practices are ‘assets’ because 
they show an organisation’s ability to adapt to changing 
situations.13–16
Capturing the dynamic nature of complex work is a 
methodological challenge. Previous research has focused 
on assessing resilience in healthcare settings and imple-
menting resilience engineering for healthcare quality 
improvement.17–22 Researchers compared how work is 
proposed to be done (Work-As-Imagined (WAI))—that is 
what people say, think or assume they do—with how work is 
actually done by healthcare practitioners (Work-As-Done 
(WAD))—that is what people actually do in practice. The 
core concept of Resilient Healthcare directs attention to 
the importance of studying how work is actually done in 
practice because clinical work does not unfold according 
to prespecified policies and guidelines.13
There is currently limited information on how intrave-
nous insulin infusions are used in hospitals. Additionally, 
although current methods for studying WAI and WAD 
have been documented, there are limitations to these. 
For example, methods to understand WAI include the 
analysis of documents, reports and protocols.17 19 WAI 
is not limited to what is written in a document and can 
include professionals’ perceptions and expectations of 
work.23 Methods to understand WAD include field obser-
vation, interviews and focus groups17 19 21 22 but these rely 
primarily on the researchers’ view or lens of how work is 
performed and poses a risk of researcher bias.
In this study, WAI will be explored using two approaches: 
(1) analysing intravenous insulin infusion guidelines 
and (2) analysing transcripts of focus group discussions 
with guideline developers, managers and healthcare 
practitioners.
A relatively new methodology called video reflexive 
ethnography (VRE),24 whereby healthcare practitioners 
can review and reflect on their in-situ practices, will be used 
to understand the interplay between WAI and WAD. As 
the core concept of Resilient Healthcare is to understand 
how work is actually done in practice and to understand 
how adaptations and adjustments are created and how 
outcomes emerge from the interplay of misalignments 
between WAI and WAD, video observations will show how 
people address their own and others’ habituated activities 
as well as their interpretations of policies and guidelines. 
Video footage of real-time practices will be shown back 
to participants in reflexive meeting sessions where they 
collectively make sense of their work and negotiate mean-
ingful, context-appropriate ways of understanding prac-
tice and enhancing work.24–28 The collaboration between 
researcher and healthcare practitioners in the reflexive 
sessions will result in the development of workable and 
realistic recommendations and solutions to increase resil-
ience in the use of intravenous insulin infusions.
Aim and objectives
The overall aim of the research is to test the feasibility 
of methods to understand the clinical work of managing 
intravenous insulin infusions to understand Resilient 
Healthcare.
Objectives
1. To describe and compare WAI and WAD in the use of 
intravenous insulin infusions in adult inpatients.
2. To understand how approximate adjustments and ad-
aptations are made in relation to the use of insulin in-
fusions.
3. To develop a model of the use of intravenous insulin 
infusions in adult inpatients.
METhodS
Setting
The study will be conducted at a single site—the Vascular 
Surgery Unit at the Oxford University Hospitals (OUH) 
NHS Foundation Trust.
Study design
This feasibility study will take place from December 2018 
to December 2019 and will involve three phases (see 
figure 1).
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Phase I: exploring WAI
Phase I will consist of (1) document analysis of guidelines 
for the use of intravenous insulin infusions and (2) focus 
groups with guidelines developers, managers and health-
care practitioners.
1. Document analysis
To develop understanding and discover insights relevant 
to what is expected when using intravenous insulin infu-
sions, hierarchical task analysis29 30 will be used to analyse 
the documents as outlined below:
 ► Define the task under analysis—which is the use of 
intravenous insulin infusions in hospitalised patients 
for glycaemic control.
 ► Collect intravenous insulin guidelines and all related 
documents.
 ► Determine the overall goal—which is treating elevated 
blood glucose in hospitalised patients.
 ► Determine the subgoals that are required to achieve 
the overall goal. An inductive thematic analysis31 32 
of the intravenous insulin infusion guidelines and 
related documents will be conducted to identify 
subgoals such as indications, prescribing, admin-
istration, monitoring, adjusting infusion rates and 
transition to other medication for diabetes where 
appropriate.
 ► Deconstruct subgoals: each subgoal will be broken 
down to further subgoals and operations.
 ► Analyse the plans (steps) required to achieve each 
goal.
2. Focus groups
Sample
Three different groups of participants will be invited to 
take part in separate focus groups. A purposive sample 
of guidelines developers (five participants), managers 
(five to seven participants) and healthcare practitioners 
working at Vascular Surgery Unit (five to seven partici-
pants) will be recruited. The inclusion and exclusion 
criteria for participants are presented in box 1.
Figure 1 Flowchart of outlined study. 
Box 1 Eligibility criteria for phase I focus group 
participants
Inclusion criteria
 ► Guideline developers responsible for developing and implementing 
local guidelines in Oxford University Hospitals (OUH) on the use of 
intravenous insulin infusions.
 ► Managers responsible for controlling resources and staffing and 
overseeing the implementation of intravenous insulin infusion 
guidelines in the Vascular Surgery Unit.
 ► Healthcare practitioners without a management role who care for 
patients requiring intravenous insulin infusions in the Vascular 
Surgery Unit.
Exclusion criteria
 ► Any participant not willing to be audiorecorded.
 ► Any healthcare practitioners not working in the Vascular Surgery 
Unit at OUH.
 ► Guidelines developers other than the Adult Inpatient Diabetes 
Specialist Team.
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Recruitment and informed consent
An email invitation letter and participant information 
sheet outlining the purpose of the study will be sent to 
potential focus group participants. On the day of the 
focus group, signed informed consent will be obtained.
Data collection
A focus group guide, informed by hospital guidelines, 
policies and protocols related to the use of intravenous 
insulin infusions will be used throughout the discussion 
(online supplementary Appendix 1). A case study will 
be presented in the last 10 min of the session aimed to 
contextualise ways of working within a plausible patient 
case.
The discussions with healthcare practitioners will be 
essential to establish relationships with the researchers 
because they are potential participants for phase II of the 
study in which work practices in-situ will be observed.
The three focus group discussions will enable compar-
ison between WAI as described by the healthcare practi-
tioners who are in direct contact with the patients and 
the guideline developers and managers who have limited 
direct patient contact. To the best of our knowledge, this 
will be the first study that compares the understanding 
of WAI between guideline developers and healthcare 
practitioners.
Focus groups will be audiorecorded and audiorecord-
ings transcribed verbatim. Any identifying information 
will be removed from the focus group transcripts.
Data analysis
An inductive thematic approach will be used with the aid 
of NVivo 12, a qualitative data management software.33
Phase II: exploring the interplay between WAD and WAI
Phase II will include analysis of patients’ records, video 
observation of WAD and reflexive analysis of the record-
ings with participating healthcare practitioners. The 
inclusion and exclusion criteria for participants are 
presented in box 2.
A mixed-methods approach using qualitative and quan-
titative methods will be used.
1. Qualitative approach: VRE
This phase will use an innovative method, VRE24 that 
has not been applied before in this study setting. As 
such, this study will test the feasibility of using the VRE 
method along with quantitative methods to understand 
how healthcare practitioners work and interact as part of 
a system while using intravenous insulin infusion. VRE is a 
qualitative research methodology that depends on collab-
oration between the researcher and the participant to 
film specific work performed by the participant.
The aim of using VRE is to improve healthcare delivery 
from the bottom up (WAD in practice) by directly 
involving healthcare practitioners in collaboration with 
the researcher in understanding the complexity of health-
care delivery.
A key concern with using video approaches is the effect 
of videoing on the practices and communications between 
the participants and the patients. A recent review found 
no evidence that video recording causes significant alter-
ation to the usual way participants behave.34 However, 
there is a possibility that changes to working practices 
may occur at the initial stages of video recording. To 
address this, the researcher will familiarise herself with 
the workflow of participants in the wards, she will observe 
and consult with participants about where she should 
best ‘locate’ herself during videoing. The researcher 
will ensure video recording is not intrusive to the daily 
routines of participants and will stop recording if appro-
priate for example, medical emergency.
Sample
In this feasibility study, two patient cases receiving intra-
venous insulin infusion will be observed to provide a 
clear understanding of actions and tasks that should 
be performed while managing patients on intravenous 
insulin infusion. The sample size of two cases was deter-
mined by time and resource constraints and Uncertanties 
about the quantity and quality of the data to analyse.
Recruitment and informed consent
Healthcare practitioners:
Three different ways will be used to recruit potential 
participants:
1. The researcher will join various existing meeting(s) 
to meet as many healthcare providers working in the 
Vascular Surgery Unit as possible, and to explain the 
VRE study.
2. A poster with details about the study will be placed in 
the staff room and on the door of the toilets until the 
completion of data collection for phase II.
Box 2 Eligibility criteria for phase II participants
healthcare practitioners
Inclusion criteria
 ► Willing to be observed by video recording.
 ► Working in the Vascular Surgery Unit at Oxford University Hospitals.
 ► Managing patients on intravenous insulin infusions.
Exclusion criteria
 ► Not involved in the use of intravenous insulin infusions.
Patients
Inclusion criteria
 ► Aged ≥18 years old.
 ► Receiving intravenous insulin infusion for at least 24 hours to treat 
hyperglycaemia.
 ► Under the care of healthcare practitioners who have consented to 
participate in this study.
 ► Able to provide informed consent.
Exclusion criteria
 ► Not willing to be observed by video recording.
 ► Not prescribed intravenous insulin infusions.
 ► On intravenous insulin infusion to treat hyperkalaemia
 ► Non-English speakers.
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3. An invitation letter and participant information sheet 
outlining the purpose of the study, the methodology 
and the design will be sent to all potential participants 
working in the Vascular Surgery Unit.
On the day of the videoing and prior to switching on the 
camera, informed consent will be obtained for observing 
the participant while using intravenous insulin infusion 
by video recording and participating in video reflexive 
meetings. In cases where the researcher is unable to 
obtain written consent before videoing, verbal consent 
will be obtained, and written consent sought as soon as 
possible afterward (posthoc consent).
Patients
The patient will be provided with an invitation letter and 
participant information sheet to explain the purpose and 
objectives of the study, which includes videorecording 
and the use of medical records. The patient will be given 
time to ask any questions about the study before giving 
written informed consent. To ensure that patients do 
not feel obliged to participate, we have included infor-
mation in the participant information sheet and consent 
form that participation is entirely voluntary. The patient 
will also have information, in the participant information 
sheet, about their right to withdraw, how to withdraw and 
what will happen to any study data collected. Prior to 
taking informed consent, the researcher will also verbally 
explain the voluntary nature of participation and their 
right to withdraw from the study. Files with participant’s 
identifiers (videos and quantitative data) will be imme-
diately deleted if a participant decides to withdraw from 
the study.
Data collection
Data will be collected in three stages:
Stage 1: familiarisation and observation of study site
The researcher will familiarise herself with the health-
care environment in the Vascular Surgery Unit by 
initially using data from focus group 3 (phase 1) to 
identify key areas of practice using intravenous insulin 
infusion to focus on during the video observation stage. 
Then, the researcher will familiarise herself with the 
environment by finding areas other than the bed space 
to be videoed such as the treatment room where infu-
sions are stocked and the electronic patient records 
are completed. The researcher will also speak infor-
mally with staff working in the Vascular Surgery Unit; 
conduct two general observations of the use of intra-
venous insulin infusions and record the observation 
in a notebook. These observations will be conducted 
for short periods of 30–60 min during normal working 
hours (day shift) and night shift.
Familiarisation will be accomplished by observing 
actual work practices and by reviewing the electronic 
patient record for historical usage of intravenous insulin 
infusions.
Stage 2: video-observation
A digital video camera will be used, and another one will 
be available on site as a backup camera in the event of 
technical failures. The researcher will video the activities 
and practices of participants while starting, monitoring, 
switching to other medications for diabetes and stop-
ping the intravenous insulin infusions. Each case will be 
observed over 24 hours (one day shift and one night shift). 
The research team will review the video footage collected 
and mask all identifiers using a video cartooniser software 
(Adobe Premiere Pro) that turns videos to cartoons. To 
reduce any potential bias, the research team consisting 
of those with different expertise and roles will select 3–4 
short video clips of interest lasting around 1.5–3 min 
for use in the reflexive meeting. Clips of interest might 
include set-up of intravenous insulin infusions, treat-
ment decisions to increase/decrease infusion rates and 
to stop intravenous insulin infusion and any additional 
unique aspects of the use of intravenous insulin infusion 
observed by the researcher.
Stage 3: reflexive meeting
Each participant will attend one arranged small group 
reflexive meeting to allow them to watch selected video 
footage, explore issues identified in observations and 
propose different solutions and recommendations to 
enhance patient safety in the use of intravenous insulin 
infusions. The researcher will be in the reflexive meeting 
discussions to facilitate the discussion, to indicate some 
issues identified through video observation, to prompt 
questions and to elicit innovations (online supplemen-
tary Appendix 2).
All reflexive meetings will be held in a private room in 
the OUH for 30–60 min and will be audiorecorded and 
then transcribed verbatim. The transcripts will provide 
the researchers with an essential record of the discussions 
and the potential solutions and plans provided by the 
participants.
Analysis
Non-identifiable codes will be used to refer to the partic-
ipants in the written materials. An inductive thematic 
approach will be used with the aid of NVivo 12 to analyse 
the recordings of the reflexive meetings. Initial themes 
derived from the analysis of data will be discussed within 
the wider research team. Master themes will be devel-
oped following identification of cross-cutting patterns 
and themes within and across the data from the video 
reflexive meetings.
To ensure trustworthiness, two members of the research 
team will independently code transcripts and differences 
in interpretation will be resolved through discussion 
between coders.
2. Quantitative approach: analysis of patients’ records
Electronic patient records of two patients whose care will 
be observed through VRE will be accessed retrospectively 
after videoing, to identify extra relevant quantitative data 
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covering the 24 hours of recording such as blood glucose 
measurements, and infusion rates, and monitoring 
frequency for the intravenous insulin infusion.
Analysis
Descriptive statistics (actual numbers and percentages) 
will be used to compare blood glucose, infusion rates and 
monitoring frequency for intravenous insulin infusion 
against the hospital’s standard protocols.
From the data, the number of hyperglycaemic 
(>12.0 mmol/L) and hypoglycaemic (<4.0 mmol/L) 
events, the cumulative time that the insulin infusions 
were held for hypoglycaemia, and the number of times 
that the patient required an intravenous ‘rescue’ 20% 
glucose infusion to treat hypoglycaemia will be calculated 
to determine the efficiency and safety of using intrave-
nous insulin infusions.35 36
The quantitative data are complementary to the quali-
tative as it is an objective measure of WAD and qualitative 
data from VRE will provide context and meaning of the 
measured data in patients’ records.
Data storage and security
All storage of data will adhere to the General Data 
Protection Regulation 2016 and the Data Protection 
Act 2018. Participant identifiable data will be stored 
on a password-protected project shared drive. The 
final study data set (focus group and reflexive meeting 
discussion transcripts’ with non-identifiable codes and 
cartoonised videos for the video observation stage) and 
data that directly underpins the research findings will 
be stored on the University of Reading Research Data 
Archive.
Phase III: developing a model for using intravenous insulin 
infusions
A comparison of discursive descriptions of findings from 
phase I and phase II will be performed to produce a 
model showing concepts that represent misalignments 
between WAI and WAD. Findings will be analysed and 
interpreted within the context of Resilient Healthcare 
theories. The model will be supplemented by summa-
ries of underpinning data used to identify and categorise 
misalignments, and the outcome of work performed. We 
will interpret the outcome of work by comparing descrip-
tions by healthcare practitioners in the reflexive meetings 
against quantitative data from patient records.
Developing a systems model based on our study data 
brings together disparate sources of information to 
provide an evidence-base for future intelligent redesign of 
the system. The model will provide a systems view of how 
intravenous insulin infusions are used; highlighting and 
providing nuanced insight into interactions between and 
among key parts of the system such as people, tasks, tech-
nology and environment, that can influence processes 
and outcomes, to explain how mismatches between WAI 
and WAD occur.
Patient and public involvement
Patients will be actively involved in the dissemination of the 
study findings through interactive workshops with patient 
representatives, healthcare providers and policy-makers 
to influence attitudes and behaviours surrounding the 
use of intravenous insulin infusions within hospitals.
dISCuSSIon
This study is designed to evaluate the feasibility of methods 
to understand the clinical work of managing intravenous 
insulin infusions and functionality of constructing a 
model of the use of intravenous insulin infusion using a 
Resilient Healthcare approach. Although many research 
studies have focused on the use of Resilient Healthcare to 
improve safety by comparing WAI with WAD,17 19 21 22 no 
study to date has examined and strengthened resilience 
in the use of specific medications such as intravenous 
insulin infusions.
To understand WAD, interviews and focus groups have 
been used in previous qualitative research to improve 
quality of care and resilience in an emergency depart-
ment17 19 clinical handovers21 37 and inpatient diabetes 
care.22 The assumption that participant’s words are reli-
able indicators of what happens in actual practice may 
be questionable. Interviews and focus groups, usually 
convened by the researcher, focus on a particular issue 
or problem. Interviewees may choose to withhold certain 
information or change it, particularly if the ‘truth’ is 
inconsistent with their preferred self-image.38 Focus 
group data are the product of context-dependent group 
interactions, and participants might or might not disclose 
certain information during the focus group discussion.39 
Observational research establishes what people actually 
do or say, rather than what they say they do. Observa-
tions can, however, include a degree of researcher bias as 
the method relies on the interpretation of observations. 
The researcher cannot ‘see’ attitudes and memories and 
so it can be difficult to create an accurate analysis from 
observation alone. To overcome problems using these 
approaches in understanding WAD and describing the 
complexity of healthcare, VRE will be used to capture 
how work with intravenous insulin infusion is actu-
ally done, what complexities healthcare practitioners 
encounter, what creative adaptations are made, and how 
they deal with expected and unexpected conditions. As a 
form of reasoning, reflexive discussions with healthcare 
practitioners will draw attention to aspects that remained 
taken for granted before witnessed on video, but which 
are critical in understanding why work was done in such 
ways. This will allow healthcare practitioners to think of 
ways to reshape their practices to improve their work and 
patient safety.
ConCluSIon
This study will test the feasibility of a mixed-methods 
approach designed to explore and strengthen resilience 
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in the use of intravenous insulin infusions by comparing 
WAI from different perspectives (guideline developers, 
managers and healthcare practitioners alongside analysing 
intravenous insulin infusion guidelines) with WAD. It will 
explore and develop understanding of the actual work in 
the use of intravenous insulin infusion through videoing 
practices and then discussing the resultant footage with 
the healthcare practitioners to identify how they do their 
work. This way of understanding resilience in healthcare 
will introduce different views on what actually happens 
in the use of an intravenous insulin infusion. It will help 
in understanding why and when there are misalignments 
between WAI and WAD, what creative adaptations may 
be performed to overcome misalignments and assist in 
the development of a model for the use of intravenous 
insulin infusion in hospitalised in-patients.
dISSEMInATIon
There are different key audiences for this research, 
including healthcare practitioners, patients and the 
public, the Joint British Diabetes Societies for Inpatient 
Care Group (JBDS-IP), The Getting It Right First Time 
(GIRFT) Programme, developers of diabetes guide-
lines at OUH, Diabetes UK and academia. The findings 
of the study including recommendations, solutions to 
enhance the safety in the use of intravenous insulin infu-
sions and the model for intravenous insulin infusion use 
will be presented to healthcare practitioners, guideline 
developers and managers at the study site. In addition, 
presentations will be given at national and international 
conferences and seminars, and workshops with patients’ 
representatives. Findings will be published in peer-re-
viewed journals. Participants and interested parties can 
request a copy of the Final Study Report. Findings will 
be of interest to those involved in safety and resilience of 
intravenous insulin infusions such as the Patient Safety 
Team NHS Improvement, GIRFT and JBDS-IP.
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